Rapamycin (Sirolimus) and Sildenafil Interaction

Why This Interaction Gets Flagged

Both sirolimus and sildenafil depend on cytochrome P450 3A4 (CYP3A4) for hepatic metabolism, and both are substrates of P-glycoprotein (P-gp) efflux transport. Drug interaction databases flag this overlap because anything that slows CYP3A4 activity will raise circulating levels of both drugs at the same time. The interaction between sirolimus and sildenafil themselves, though, is not one of mutual inhibition. Neither drug is a strong inhibitor or inducer of CYP3A4 at therapeutic doses.

The FDA-approved prescribing information for sirolimus (Rapamune) identifies strong CYP3A4 inhibitors and inducers as the agents requiring dose adjustment or avoidance [1]. Sildenafil's label (Viagra/Revatio) carries similar language about CYP3A4 inhibitors increasing sildenafil plasma concentrations [2]. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics demonstrated that ketoconazole (a potent CYP3A4 inhibitor) increased sildenafil AUC by 182% [3]. That same class of inhibitor raises sirolimus trough concentrations by 5- to 10-fold, according to transplant pharmacokinetic data [1].

The clinical scenario that demands the most caution is not the two-drug pairing alone. It is the three-drug scenario: sirolimus plus sildenafil plus a strong CYP3A4 inhibitor such as itraconazole, voriconazole, or a protease inhibitor. In that triad, sildenafil exposure may double or triple while sirolimus levels climb to toxic ranges. Transplant recipients on calcineurin inhibitor-free regimens using sirolimus should have this triad scenario evaluated at every medication reconciliation.

The CYP3A4 and P-glycoprotein Overlap Explained

CYP3A4 handles roughly 50% of all clinically used drugs, and both sirolimus and sildenafil sit in that group [4]. Sirolimus undergoes extensive first-pass metabolism by CYP3A4 in the gut wall and liver, producing multiple hydroxylated and demethylated metabolites. Its oral bioavailability is approximately 14% in healthy volunteers, a figure heavily influenced by intestinal CYP3A4 and P-gp activity [1].

Sildenafil follows a parallel route. CYP3A4 is its primary metabolic enzyme, with CYP2C9 contributing a minor secondary pathway. The drug is converted to N-desmethyl sildenafil, an active metabolite with about 50% the potency of the parent compound and its own 4-hour half-life [2].

P-glycoprotein adds another layer. Both drugs are P-gp substrates, meaning they are actively pumped out of enterocytes back into the gut lumen. Inhibition of P-gp (by cyclosporine, for example) increases absorption of both. A study in Transplantation showed that switching from cyclosporine to sirolimus-based immunosuppression reduced P-gp-mediated drug interactions substantially, but the shared substrate status with sildenafil remains relevant when P-gp inhibitors are part of the regimen [5].

The practical distinction: sirolimus is a narrow therapeutic index drug. Small changes in blood levels matter. Sildenafil has a wide therapeutic window. The same 30% increase in AUC that would be clinically insignificant for sildenafil could push sirolimus from therapeutic into toxic territory. This asymmetry means monitoring priorities should focus on sirolimus trough levels rather than sildenafil dose adjustments.

Pharmacodynamic Considerations: Blood Pressure and Beyond

The pharmacodynamic side of this interaction centers on hemodynamics. Sildenafil causes vasodilation through nitric oxide-mediated increases in cyclic GMP. It lowers systolic blood pressure by an average of 8 to 10 mmHg in healthy subjects [2]. Sirolimus does not have direct vasodilatory properties, but transplant patients on sirolimus-based regimens may be on concurrent antihypertensives, creating additive blood pressure lowering when sildenafil is introduced.

A retrospective cohort analysis published in the American Journal of Transplantation examined PDE5 inhibitor use in renal transplant recipients on various immunosuppressive backgrounds. The study found no statistically significant increase in hypotensive events among patients on sirolimus-based regimens compared to those on tacrolimus or cyclosporine [6]. The sample was small (N=87), but the signal was reassuring.

Pulmonary hypertension adds a separate dimension. Sildenafil is FDA-approved as Revatio (20 mg three times daily) for pulmonary arterial hypertension (PAH). Transplant recipients, particularly lung and heart-lung recipients, may require both sirolimus for immunosuppression and sildenafil for PAH management. In this context, the drugs are used at different doses, and the interaction profile shifts. A case series in The Journal of Heart and Lung Transplantation documented stable sirolimus trough levels in four lung transplant patients started on sildenafil 20 mg TID, with no dose adjustments required over 12 months of follow-up [7].

There is no synergistic toxicity between mTOR inhibition (sirolimus's mechanism) and PDE5 inhibition (sildenafil's mechanism) at the molecular level. Some preclinical research has explored whether mTOR inhibitors and PDE5 inhibitors might have complementary effects on vascular remodeling, but this remains investigational [8].

Dose Adjustment and Monitoring Protocol

No published guideline mandates a specific dose reduction of either drug when the two are co-prescribed. The approach in clinical practice is monitoring-based rather than empiric dose reduction.

For transplant patients on standard-dose sirolimus (target trough 5 to 15 ng/mL), the recommended protocol when adding sildenafil includes checking a sirolimus trough level at baseline before starting sildenafil, repeating the trough 5 to 7 days after sildenafil initiation, and monitoring blood pressure within the first 2 to 4 hours after the initial sildenafil dose. If the sirolimus trough rises more than 20% above baseline, investigate other causes (dietary changes, new medications, grapefruit intake) before attributing the change to sildenafil alone.

For patients using low-dose sirolimus off-label (1 to 6 mg weekly for longevity protocols), the interaction risk is substantially lower. Weekly dosing produces peak-and-trough pharmacokinetics very different from daily transplant dosing. Sildenafil's 3- to 5-hour half-life means the drugs are rarely at peak concentrations simultaneously unless taken on the same day. Dr. Matt Kaeberlein, a researcher who has published on rapamycin's geroprotective effects, has noted that "the drug interaction profile of weekly low-dose rapamycin is fundamentally different from daily transplant dosing, and most flagged interactions are clinically irrelevant at these exposures" [9].

Sildenafil dose adjustment is generally unnecessary. The standard starting dose of 50 mg (with a 25 to 100 mg as-needed range) does not need modification based solely on sirolimus co-administration [2]. If a strong CYP3A4 inhibitor is also present, sildenafil should be started at 25 mg regardless of sirolimus status, per the Viagra prescribing information [2].

What About Other PDE5 Inhibitors?

Tadalafil (Cialis) has a longer half-life of 17.5 hours compared to sildenafil's 3 to 5 hours. This means tadalafil and sirolimus share a longer window of overlapping CYP3A4 competition. The FDA label for tadalafil recommends a maximum of 10 mg every 72 hours when used with strong CYP3A4 inhibitors [10]. While sirolimus is not a strong CYP3A4 inhibitor, the combination of daily tadalafil (2.5 to 5 mg for BPH or daily ED therapy) with daily sirolimus creates more sustained competitive substrate binding at CYP3A4 than as-needed sildenafil use.

Vardenafil (Levitra) is the most CYP3A4-dependent of the three major PDE5 inhibitors and carries the most conservative labeling around CYP3A4 interactions [11]. Avanafil (Stendra), the newest PDE5 inhibitor, also undergoes CYP3A4 metabolism but has limited pharmacokinetic interaction data in transplant populations.

For patients on sirolimus who need a PDE5 inhibitor, sildenafil's shorter half-life and larger evidence base in transplant populations make it the most predictable choice.

High-Risk Populations and Contraindications

The absolute contraindication that applies to all PDE5 inhibitors, regardless of sirolimus status, is concurrent nitrate use. Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) combined with sildenafil can produce severe, life-threatening hypotension. This pharmacodynamic interaction is unrelated to CYP3A4 metabolism and is not altered by sirolimus [2].

Transplant recipients represent a population with elevated cardiovascular risk. The American Heart Association's 2012 scientific statement on sexual activity and cardiovascular disease stratifies patients into risk categories [12]. Patients with stable graft function on sirolimus monotherapy or dual therapy generally fall into the low-to-intermediate risk category, where PDE5 inhibitor use is appropriate after clinical evaluation.

Hepatic impairment amplifies the interaction. Both sirolimus and sildenafil rely on hepatic CYP3A4 metabolism. In patients with Child-Pugh class A or B cirrhosis, sildenafil clearance is reduced by 47%, and the prescribing information recommends a 25 mg starting dose [2]. Sirolimus clearance is reduced by approximately 35% in patients with mild-to-moderate hepatic impairment [1]. The combination in liver-impaired patients warrants closer monitoring of both sirolimus trough levels and hemodynamic response to sildenafil.

Patients over age 65 have reduced CYP3A4 activity on average. Sildenafil plasma concentrations are approximately 40% higher in healthy elderly subjects (age >65) compared to younger adults [2]. When elderly patients are also on sirolimus, a conservative sildenafil starting dose of 25 mg is prudent, though this recommendation derives from the sildenafil label's age-based guidance rather than a specific sirolimus interaction study.

Grapefruit, St. John's Wort, and Dietary Interactions

Grapefruit juice is a moderate CYP3A4 inhibitor that increases both sirolimus and sildenafil levels. The sirolimus prescribing information specifically states that patients should avoid grapefruit juice [1]. A crossover study in British Journal of Clinical Pharmacology measured a 23% increase in sildenafil AUC after grapefruit juice consumption [13]. For patients taking both drugs, grapefruit avoidance is not optional.

St. John's wort (Hypericum perforatum) is a potent CYP3A4 inducer. It can reduce sirolimus trough levels by 50% or more, potentially leading to graft rejection in transplant patients [1]. It also reduces sildenafil efficacy, though this is less clinically consequential. The directive is simple: St. John's wort is contraindicated with sirolimus regardless of sildenafil use.

Turmeric (curcumin) supplements, increasingly popular in longevity-focused populations who may also be taking low-dose rapamycin, have shown mild CYP3A4 inhibitory activity in vitro. Clinical significance at typical supplement doses remains uncertain, but patients should disclose supplement use during medication reconciliation [14].

Counseling Points for Patients

Patients prescribed both medications should receive specific guidance. Take sildenafil on a separate day from weekly rapamycin if using a longevity-dose schedule. Report any dizziness, lightheadedness, or visual disturbances after the first combined use. Do not take sildenafil with nitrate medications under any circumstance. Avoid grapefruit and grapefruit juice entirely. Inform all prescribers about both medications, particularly before any new antibiotic or antifungal is started. If starting a new azole antifungal or macrolide antibiotic, hold sildenafil until the prescriber confirms safety, and expect a sirolimus trough level check within 5 to 7 days.

A sirolimus trough drawn 24 hours after a sildenafil dose (for patients on daily sirolimus) provides the most informative data point for assessing whether the combination has meaningfully altered sirolimus pharmacokinetics. Any trough above 20 ng/mL in a transplant patient, or any trough above 8 ng/mL in an off-label longevity user targeting sub-therapeutic immunosuppressive levels, warrants prompt clinical review.